Antimicrobial Action of the Cyclic Peptide Bactenecin on Burkholderia pseudomallei Correlates with Efficient Membrane Permeabilization

Kanjana Madhongsa¹,²*, Supaluk Pasan¹,², Onanong Phophetleb¹,², Sawinee Nasompag¹,², Sompong Thammasirirak¹,², Sakda Daduang¹,², Suwimol Taweechaisupapong³,⁴, Andrei L. Lomize⁵, Rina Patramanon¹,²*¹

Abstract

Burkholderia pseudomallei is a category B agent that causes Melioidosis, an acute and chronic disease with septicemia. The current treatment regimen is a heavy dose of antibiotics such as ceftazidime (CAZ); however, the risk of a relapse is possible. Peptide antibiotics are an alternative to classical antibiotics as they exhibit rapid action and are less likely to result in the development of resistance. The aim of this study was to determine the bactericidal activity against B. pseudomallei and examine the membrane disrupting abilities of the potent antimicrobial peptides: bactenecin, RTA3, BMAP-18 and CA-MA. All peptides exhibited >97% bactericidal activity at 20 μM, with bactenecin having slightly higher activity. Long term time-kill assays revealed a complete inhibition of cell growth at 50 μM bactenecin and CA-MA. All peptides inhibited biofilm formation comparable to CAZ, but exhibited faster kinetics (within 1 h). Bactenecin exhibited stronger binding to LPS and induced perturbation of the inner membrane of live cells. Interaction of bactenecin with model membranes resulted in changes in membrane fluidity and permeability, leading to leakage of dye across the membrane at levels two-fold greater than that of other peptides. Modeling of peptide binding on the membrane showed stable and deep insertion of bactenecin into the membrane (up to 9 Å). We propose that bactenecin is able to form dimers or large β-sheet structures in a concentration dependent manner and subsequently rapidly permeabilize the membrane, leading to cytosolic leakage and cell death in a shorter period of time compared to CAZ. Bactenecin might be considered as a potent antimicrobial agent for use against B. pseudomallei.

Introduction

Burkholderia pseudomallei is a category B agent and causative agent of melioidosis, a disease endemic in tropical areas such as Southeast Asia, northern Australia, the Indian subcontinent, Iran, and Central and South America, as well as other temperate regions that border the equator. B. pseudomallei can be found in moist soil, still water, and paddy fields and can infect humans through punctured skin or inhalation [1]. Infection of B. pseudomallei results in a wide range of clinical signs and symptoms, with septic shock as the most severe manifestation. Recurrence of infection is common even after treatment with a complete antibiotic regimen [2]. B. pseudomallei is intrinsically resistant to many antibiotics including first and second generation penicillins, chloramphenicol, tetracycline, and aminoglycosides, but is usually susceptible to CAZ, imipenem, carbapenems, amoxicillin-clavulanate, and chloramphenicol. A 20-week standard treatment includes an intravenous phase and an eradication phase through oral administration [2,3]. The mortality rate due to melioidosis is about 20% in northern Australia and 50% overall in the less developed northeast region of Thailand [2].

Antimicrobial peptides (AMPs) are part of the innate defense system found in a wide range of organisms including insects, plants, and animals, and are used by these organisms to protect themselves from pathogenicmicrobe infection [4]. Unlike antibiotics, the killing mechanism of AMPs are target non-specific and usually involve membrane disruption, making them ideal for use against antibiotic-resistant pathogens [5]. AMPs generally consist of 20–40 amino acids, and are structurally organized in
such a way to make them amphipathic, with one side consisting of positively charged residues and the other surface of hydrophobic residues. AMPs exhibit a broad spectrum of antimicrobial activity against Gram negative and Gram positive bacteria, fungi, and parasites. More specifically, AMPs that target Gram-negative bacteria interact with the negatively charged lipopolysaccharides (LPS) on the outer membrane via electrostatic and Van der Waals forces [6]. Examples of AMPs include human cathelicidin LL-37 [7], bovine Indolicidin [7] and bactenecin [8], bovine myeloid antimicrobial peptide-18 (BMAP-18) [9], a Cecropin A (1–8)-Magainin A (1–12) hybrid peptide (CA-MA) [10] and commensal-derived RTA3 [11].

Previous studies have reported that cathelicidin-derived peptides LL-37 and LL-31, Defensin HNP-1, histatin and histatin variants, and lactoferrin could inhibit the growth of B. pseudomallei [12,13]. Comparison of the antimicrobial activity of these peptides on B. pseudomallei showed that the LL-31 peptides exhibited the most effective killing activity against all isolates independent of the LPS phenotype. Moreover, the LL-37 and LL-31 peptides could inhibit biofilm formation of B. pseudomallei. Despite the discovery of several new AMPs, little information about AMPs against B. pseudomallei is known. Attempts have been made in this study to search for more AMPs active against this virulent pathogen. Amongst hundreds of AMPs that have been reported to have potent antibacterial activity, four peptides were selected under the basis of having the strongest activity against P. aeruginosa, the most genetically related species to B. pseudomallei. These are bactenecin (RLCRIV-VIRVCR) [8], BMAP-18 (GRWKRWRKKWKLLWKKLS) [9], CA-MA (KWKLFFKIGIFKFLHSAKKF) [10], and RTA3 (RPAFKKAARFVMRACV) [11].

Bactenecin is a 12-aa looped antimicrobial peptide with an intracellular disulfide bond originally found in the granules of bovine neutrophils [14]. Intensive study on this short cationic peptide to modify its selectivity and activity expanded from engineering bactenecin to be in a looped or linear form to performing amino acid substitutions in order to increase or decrease the peptide hydrophobicity [15–17]. Recent reports also show that the oligomeric status of bactenecin determines its mode of action and dictates the strength of the antimicrobial activity [18–20].

Bovine myeloid antimicrobial peptide-18 (BMAP-18) is the cationic N-terminal domain of the cathelicidin member, BMAP-27, but has drastically reduced mammalian cytotoxicity [21]. BMAP-18 and its analogs exert a bacterial killing effect via forming small pores in the cell membrane, resulting in depolarization of ion flux [9]. In addition, BMAP-18 has been reported to efficiently kill African trypanosomes, fish trypanosomes and Leishmania parasites in vitro and also inhibit their life cycle stages [22].

Cecropin (1–6)-Magainin (1–12) or CA-MA is a hybrid peptide designed from the N-terminal cationic α-helix of cecropin A and the C-terminal amphipathic α-helix of magainin 2 [23]. CA-MA has potent antimicrobial activities against Escherichia coli and Bacillus subtilis, without hemolytic activity [24]. Analogs of CA-MA also exhibited strong antimicrobial activities due to the cationic and amphipathic structure [25,26].

RTA3 is an amphipathic helical peptide isolated from the commensal organism, Streptococcus mitis. It exhibited strong broad spectrum antimicrobial activity with minimal cytotoxicity both in vitro and in vivo [27]. Thermodynamic measurements of the membrane interaction demonstrated that RTA3 and its variants show differential outer and inner membrane-specific perturbation, which explains the modulation of antimicrobial activity [11].

Here, we determine the antimicrobial activity of these peptides against B. pseudomallei H777, the clinical isolate from blood with high biofilm production levels [28]. We also dissected the mechanism of action of these peptides using live B. pseudomallei, model membranes, and molecular modeling approaches.

Materials and Methods

Materials

The peptides bactenecin, BMAP-18, CA-MA and RTA3 were synthesized by Tufts University Core Facility (Boston, MA) using standard fluoren-9-ylmethoxycarbonyl (Fmoc) solid-phase synthesis. The crude peptides were purified by reverse phase HPLC after which the peptides were confirmed to be greater than 99% pure by analytical HPLC and analyzed by mass spectrometry. N-phenyl-1-naphthylamine was purchased from Bio-Rad, USA. Polymyxin B was purchased Sigma-Aldrich, USA. Polymyxin B Bodipy FL conjugate was purchased from Molecular Probes (Leiden, The Netherlands). CAZ was purchased from GlaxoSmithKline, Italy. Luria broth and nutrient agar were purchased from Himedia, India. Formvar copper coated grids were purchased from Tedpella, USA. 96-well fluorescence plates were purchased from Corning, USA. Glutaraldehyde and formaldehyde were purchased from Poison, Australia.

Bacterial strains and growth conditions

Burkholderia pseudomallei isolate H777 and Pseudomonas aeruginosa ATCC 27853 were used in this study. B. pseudomallei isolate H777 was kindly provided by Dr. Surasakdi Wongratanacheewin, Melioidosis Research Center, Khon Kaen University, Thailand. B. pseudomallei isolate H777 was first isolated from the blood of a patient in northeast Thailand in 2001. This wild-type isolate is characterized by the ability to produce high levels of biofilm, with a relative biofilm-forming capacity of 3.264 (OD 630) [28]. P. aeruginosa is a commonly found bacteria that causes disease which results in damage of tissue or inflammation and sepsis in patients with compromised immunity. P. aeruginosa ATCC 27853 is commonly used for antimicrobial susceptibility tests [29]. The media used in this study were Luria broth (LB) and nutrient agar (NA). The bacterium was streaked on NA and then cultured at 37 °C overnight. Colonies were picked and cultured in LB at 37 °C in an incubator overnight and then subcultured at 37 °C in a 200 rpm shaker-incubator for 1.5 h to yield a mid-logarithmic growth phase culture.

Antimicrobial activity

The killing activities of all peptides against B. pseudomallei H777 were determined by a colony culturing assay as described
previously [12,13]. Briefly, B. pseudomallei H777 cells were washed and resuspended to a 10^6 CFU/mL in 1 mM potassium phosphate buffer (PPB) pH 7.0. Bacterial suspension was added at equal volumes to solutions of AMPs to attain final concentrations of 5, 10 and 20 μM for all peptides studied. Bacterial suspension without peptide was the control. Following incubation at 37°C for 1 h, the incubation mixture was serially diluted into a physiological concentration of saline and plated in triplicate on NA. Colonies were counted after 24 h of incubation at 37°C. Each assay was performed on two separate occasions, with triplicate determinations each time.

Long-term killing kinetics

Bactericidal kinetics of the cationic antimicrobial peptides were determined using a culture of B. pseudomallei H777 re-suspended in 1 mM potassium phosphate buffer (PPB) at a concentration of 1×10^6 CFU/mL [12,13]. Each peptide was added to the bacterial suspension to a final concentration of 25, 50 and 100 μM and was incubated in a 200 rpm shaker incubator at 37°C. At indicated times (0, 1, 2, 3, 4, 5, 6 and 24 h), samples were taken, serially diluted, plated in triplicate on NA and incubated for 24 h to allow colony counting. A bactericidal effect was defined as a ≥3log10 reduction in CFU/mL compared to the initial inoculum.

Prevention of biofilm formation

Effect of peptides in preventing biofilm formation was determined in 96-well microplates [30]. B. pseudomallei H777 were cultured in LB for 16 h and then diluted to 20% in fresh sterile medium. The cell culture was then incubated in a 200 rpm shaker-incubator at 37°C for 2 h. Cell cultures were diluted to approximately 10^6 CFU/mL in fresh sterile medium, and each well of the microplate was filled with 100 μL of cell suspension with the peptides to a final concentration of 20, 50 or 100 μM. The plates were incubated at 37°C for the indicated times (1, 2, 3 and 4 h), after which the bacterial cells were spun and washed three times with 1 mM PPB, pH 7.0 to remove free peptide. The bacterial cells were resuspended in fresh sterile medium and cultured for another 2 days for biofilm formation. After 2 days, bacteria were washed three times with 0.9% (w/v) NaCl. The biofilm on the plates was then stained with 0.1% (w/v) crystal violet solution for 10 min, washed and then dissolved with 33% (v/v) acetic acid for 10 min. Biofilm mass was determined by measuring the absorbance at 550 nm using a microtiter plate reader.

LPS-binding assay (PMB-BY displacement)

The binding of the cationic antimicrobial peptides to LPS was evaluated using a Polymyxin B-BODIPY (PMB-BY) displacement assay [31]. B. pseudomallei H777 were grown to mid-log phase in LB, spun down, and washed twice with an equal volume of 50 mM Tris buffer supplemented with 1.5 mM ONPG and 50 μM final concentration of peptides. The rate of permeability was evaluated through ONPG hydrolysis by measuring absorbance at 415 nm in SpectraMax M5 at indicated times (0, 15, 30, 45, 60 and 120 min)
DPH-anchored LUVs were incubated in the dark at room temperature for at least 1 hr and then peptides at 5, 10, 20, 25, or 50 μM was added and incubated for 30 min further. The cuvette containing the fluorescent samples was placed in a temperature controlled holder at 37°C for 10 min, and readings were taken at intervals of 2 s. The excitation and emission wavelengths were 355 and 424, respectively. The polarization values (r) of the samples were calculated by the fluorescence data manager program using the following equation:

\[ r = \frac{I_{VV} - GI_{VH}}{I_{VV} + 2GI_{VH}} \]

Where \( I_{VV} \) and \( I_{VH} \) are the intensities of the fluorescence (in arbitrary units) emitted parallel and perpendicular to the direction of the vertically polarized excitation light, respectively. G is the correction factor (\( G = \frac{I_{VV}}{I_{VH}} \)) for the optical system given by the ratio of the vertically to the horizontally polarized emission components when the excitation light is polarized in the horizontal direction.

Electron microscopy

The bacterial cultures at 10^5 CFU/mL were treated with or without 50 μM peptide for 2 h. Medium and peptide were removed by centrifuging and washing the cells in 1 mM PPB. The cells were fixed with 4% glutaraldehyde and 4% formaldehyde for 30 min, and the bacteria were dropped onto Formvar-coated grids (Tedpella, USA) and rinsed with water. The bacteria were stained with 5% uranyl acetate and silver acetate and electron micrographs were taken with a TECNAI G2 20(FEI) microscope.

Figure 1. Bactericidal activities of four antimicrobial peptides against *B. pseudomallei*. Bacterial suspensions were incubated with 5(black), 10(dark grey) and 20(light grey) μM of cationic antimicrobial peptides or CAZ for 1 h. The viability of bacterial cells was determined by a plate counting technique and the data are presented as the mean and the standard deviation of two independent experiments performed in triplicate. doi:10.1371/journal.pntd.0002267.g001
the gauche-gauche-gauche conformation, in agreement with experimental data [45]. After substituting all the residues in the template using QUANTA (Accelrys Software Inc.) and minimization of local energy by CHARMM (200 steps with adopted basis Newton-Raphson method, ε = 10), the models were positioned in the lipid bilayer using our program PPM 2.0 [38].

Results

Antimicrobial activity of peptides against B. pseudomallei

The bactericidal activities of cationic peptides against B. pseudomallei are shown in Fig. 1. At a peptide concentration of 5 μM, bactenecin exhibited the strongest (96.1%) bactericidal activity. The antibiotic ceftazidime (CAZ) resulted in only 75.4% activity, and RTA3 exhibited the lowest bactericidal activity (59.9%). When cells were treated with a higher concentration of peptide (10 μM), a greater bactericidal effect was observed for all peptides. At 20 μM, bactenecin, CA-MA, BMAP-18, RTA3, and CAZ exhibited 99.8%, 97.8%, 99.7%, 97.3%, and 90.9% killing activities, respectively.

We next examined the long-term killing kinetics of the peptides in comparison to CAZ (Fig. 2). Under untreated conditions, the bacterial cell density increased from $6.3 \times 10^6$ to $11.3 \times 10^6$ CFU/mL within 24 h. Addition of 20 μM bactenecin, CA-MA, or BMAP-18 reduced the number of CFU/mL within the first 3 h, after which the bacterial cells grew to $>10^5$ CFU/mL within 24 h. A complete killing was observed for cells treated with 20 μM CAZ, 50 μM bactenecin, 50 μM BMAP-18, 100 μM CA-MA, or 100 μM RTA3. Results from Fig. 1 and Fig. 2 indicate that all peptides have strong inhibition effects at early incubation times, but higher concentrations of peptide is needed to completely inhibit growth under longer incubation times. In addition, bactericidal action of the peptides appeared to be faster than that of CAZ, as seen by the complete drop in cell growth within only 1 hr at the higher concentration of peptides (Fig. 2A–D) as compared to 6 hrs for CAZ (Fig. 2E).

Effect of peptides on prevention of biofilm formation

Biofilm formation inhibition activities of bactenecin, BMAP-18, CA-MA and RTA3 were determined and compared to that of CAZ (Fig. 3). All peptides showed more than 50% inhibition of biofilm formation at all concentrations and at all time points, except for CA-MA at 20 μM at 1 h (48.0%). Lowest inhibitory activity (48.0–58.3%) was found in cells treated with 20 μM peptide. No significant differences in biofilm inhibition were found between moderate (50 μM) and high (100 μM) concentrations of all 4 peptides (60.0–74.8% at 50 μM and 65.0–74.0% at 100 μM). The results indicate that increasing peptide concentration or increasing incubation time only slightly increased inhibitory activities. When comparing biofilm inhibition of peptides and CAZ, the inhibitory activities were not significantly different. However, CAZ appeared to have a slower inhibitory effect than that of the peptides, as we observed significantly lower activity at all concentrations after 1 h incubation (6.2%, 21.8%, and 41.1% at 20, 50 and 100 μM CAZ, respectively). However, the biofilm formation inhibition activity of CAZ dramatically increased after 2 h of treatment and was stable even after longer treatment times at all concentrations tested.
Mechanism of action of peptides against *B. pseudomallei*

In order to further determine the reasons underlying the stronger inhibitory activity of bactenecin, membrane binding and permeability of four of the peptides were compared using live cell membranes and model membranes. Initial attachment of peptide to bacterial cells involves binding of the peptide to LPS. We found that bactenecin and the control peptide antibiotic Polymyxin B (PMB) exhibited stronger LPS binding than BMAP-18 CA-MA and RTA3 (Fig. 4A). Bactenecin and PMB at 5 μM peptide concentrations resulted in 15% displacement of PMB-BY. Displacement appeared to reach saturation at 10 μM peptide, and did not increase with further addition of peptide. Similar saturation was found in BMAP-18 and CA-MA, but these two peptides caused only 5–7% displacement. RTA3 did not exhibit LPS-binding.

The ability of the peptides to permeabilize the outer membrane was observed using NPN uptake on live *B. pseudomallei*. Increase in NPN fluorescence was due to outer membrane disintegration from peptide permeabilization. The results show that the ability of the peptides to disrupt the outer membrane ranked from strongest to weakest was: BMAP-18>CA-MA>bactenecin>PMB>RTA3 (Fig. 4B). In order to complete membrane permeabilization, peptides translocation to inner membrane is one of the critical steps. We observed the ability of peptides to permeate inner (plasma) membrane using the lactose permease deficient strain *E. coli* MG 1655 [46]. Inner membrane disruption was indicated by leakage of β-galactosidase to catalyze a nonchromogenic substrate ONPG to be a yellow product ONP, as shown in Fig. 4C. Bactenecin induced inner membrane permeation at a higher rate than the three other peptides, as reflected in the greater slope of ONPG hydrolysis at 0–1 h. Permeabilization appeared to halt after 1 h. BMAP-18 showed stronger permeation than bactenecin and other peptides during the first 15 min, after which, the effect seemed to halt and slightly decrease. In sum, both assays displayed differences in the ranking of peptides in their abilities to disrupt the outer and inner membranes. The control, Polymyxin B, a well-known peptide antibiotic, exhibited differing abilities to permeabilize the inner and outer membranes as well when measured by these assays. We found that...
while it appeared to fail to disrupt the outer membrane, it exhibited the greatest ability to permeabilize the inner membrane in comparison to the other peptides tested (Fig. 4B–C).

Next, we used model membranes to observe the direct action of the peptides on the phospholipid bilayers. LUVs were prepared containing the fluorescent probe/quencher ANTS/DPX. Leakage of the dyes was highest when the LUVs were treated with bactenecin, giving a fluorescence intensity value of about 55% the maximum fluorescence for complete dye leakage, as determined by disrupting the LUVs with TTX-100 detergent (Fig. 5A). The rest of the peptides caused dye leakage as following: BMAP-18 35%, CA-MA 22%, and RTA3 0%. Interestingly, interaction of peptides with DPH-anchored LUVs showed fluctuation of the dye molecule in phospholipid bilayers as present in fluorescence anisotropy. The results suggest that all peptides induced changes in membrane fluidity (Fig. 5B). Taken results in Fig. 5A and Fig. 5B together, it indicated that although all peptides could perturb the membrane to an extent, bactenecin appeared to be able to induce either more or larger pores on membrane.

We further provide morphological evidence of these peptides acting on *B. pseudomallei* by negative staining and electron microscopy as shown in Fig. 6. Cell death caused by CAZ was characterized by cell shape deformation in the absence of cytosolic content release (Fig. 6B). In contrast, the cell death that was caused by the antimicrobial peptides was characterized by only slight cell shrinkage but with cytosolic release due to the leakiness of the membrane (Fig. 6C–F).

### Modeling of membrane-bound antimicrobial peptides

Lastly, we performed computational modeling of peptide binding to simulated lipid bilayers (Fig. 7). Calculations using the thermodynamic model of the helix-coil transition and our PPM program for positioning of proteins in membranes suggest that both the RTA3 and BMAP-18 peptides are unfolded in water but form an amphiphatic α-helix in the membrane-bound state. The membrane-bound cecropin-magainin hybrid peptide (CA-MA) may form either one continuous α-helix or two shorter helices separated by a Gly-Ile-Gly motif (Fig. 7A–C). Circular dichroism analysis of these peptides support the modeling results, as we found a high percentage of β-sheet in bactenecin, but high percentage of α-helix in the other three peptides in a trifluoroethanol, a membrane mimicking environment (Fig. S1 and Table S1). The calculated membrane binding energies of these peptides in the α-helical conformation were larger for BMAP-18 (∆Gbinding = -11.9 kcal/mol) than for CA-MA (∆Gbinding = -7.8 kcal/mol) and RTA3 (∆Gbinding = -4.2 kcal/mol). The hydrophobic region of CA-MA, including Trp3, was predicted to insert deeper into the membrane hydrocarbon core (8.2 Å from the lipid carbonyl groups) than the nonpolar residues of RTA3 and BMAP-18.

Recent experimental studies indicated that Arg-rich bactenecin has a β-turn structure stabilized by a disulfide bridge in a distinct conformation that does not change significantly upon incorporation of the peptide into the lipid monolayer [45]. In addition, it has been observed that bactenecin is prone to self-association and

---

**Figure 4.** LPS binding and membrane permeabilization of four peptides on living bacterial cells. (A) LPS binding of peptides measured with a polymyxin B-BY displacement assay. *B. pseudomallei* suspensions at 1 × 10⁸ CFU/ml were incubated with PMB-BY for 1 hour and treated with the peptides at indicated concentrations. Fluorescence of PMB-BY was monitored 30 min after adding peptides. (B) Permeabilization of the outer membrane by the peptides was observed by NPN uptake. Fluorescence of PMB-BY was monitored 30 min after adding peptides. (C) Permeabilization of the inner membrane by the peptides was assayed by ONPG hydrolysis. The E. coli MG 1655 cell suspension was incubated with 50 μM peptides. Activity of leaked β-galactosidase was measured using ONPG as substrate. ONPG hydrolysis was monitored for 0–2 h. Data are the mean of two independent experiments performed in triplicate. Data are the mean of two independent experiments performed in triplicate.

doi:10.1371/journal.pntd.0002267.g004

**Figure 5.** Peptide binding to model membranes resulted in membrane leakage and altered membrane fluidity. (A) Peptide binding induced leakage of ANTS/DPX-trapped model membranes was observed. After addition of 20 μM peptides into the liposome suspension, leakage was monitored by measuring an increase in ANTX fluorescence intensity at 530 nm, with the excitation at 353 nm for 360 sec. (B) Changes in fluidity of model membranes was observed. Fluorescence anisotropy of DPH anchored in LUVs (EYPG/PC 3:1) was calculated from parallel and perpendicular fluorescence intensity values recorded at excitation 355 and emission at 424 nm, after addition of 5, 10, 20, 25 and 50 μM peptide into 10 mM HEPES buffer pH 7.4.

doi:10.1371/journal.pntd.0002267.g005
formation of filament-like structures on membrane surfaces [45]. Therefore, we modeled the structure of bactenecin as a β-hairpin capable of self assembling into a larger β-sheet. The most probable structure of the disulfide-bridged β-hairpin with nine residues in the loop can be determined based on the requirement that a disulfide bond should be formed between the non-hydrogen-bound pair of cysteine residues in the β-sheet [48]. The β-turn portion of the loop may be composed of the Val6-Val7-Ile8 residues in an αR-β conformation [49] (Fig. 7D, Fig. 8). Dimerization, especially of the N/N type, allows for deeper penetration of bactenecin into the membrane core, which significantly increases peptide interactions with the membrane (Table 1). Indeed, while the bactenecin monomer was calculated to have a surface orientation on the membrane in which the maximal penetration depth of the peptide is 3.8 Å, both antiparallel and parallel dimers bind to the membrane much more tightly than the monomer (ΔGbinding equal to −6.6 and −8 kcal/mol for the antiparallel and parallel dimers respectively, as compared to −3.7 kcal/mol for the monomer) and are inserted much deeper into the membrane core (up to ~9 Å depth).

**Discussion**

The *Burkholderia* genus is reported to be highly resistant to antimicrobial peptides including polymyxin B [50,51]. When

---

**Figure 6.** Electron micrographs of *B. pseudomallei* deformation and cytoplasmic leakage caused by four antimicrobial peptides. Bacterial suspensions at 1 × 10⁶ CFU/ml were incubated with or without 50 μM of the peptides for 2 h in a 37°C incubator. Untreated bacterial cells had smooth membranes and uniform shape (A) but shrunk when they were treated with CAZ (B). Cell deformation and leakage of cytosol was observed upon peptide treatment (C: bactenecin, D: BMAP-18, E: CA-MA, and F: RTA3). Scale bar represents 500 nm.

doi:10.1371/journal.pntd.0002267.g006
comparing the antimicrobial properties of the same antimicrobial peptide towards different bacterial species, the MIC value for *Burkholderia* is several magnitudes greater than those of *Pseudomonas aeruginosa* or *Escherichia coli*. This is believed to be due to the production of a unique biofilm and the different type of LPS moiety on the *Burkholderia* spp. outer membrane. However, recent findings provide evidence of effective *B. pseudomallei* inhibition by a group of cationic peptides including LL37, Lactoferrin, and Histatin [12,13]. Here, our study expands on these findings, and provides evidence of antimicrobial peptide efficacy against *B. pseudomallei* H777, the high biofilm-producing clinical isolate. This study demonstrates the bactericidal effects of four cationic peptides with experimental and computational evidence explaining the greater efficacy of cyclic bactenecin as compared to the linear CA-MA, RTA3 or BMAP-18 peptides. Our study appears to be the first report on antimicrobial peptides against *B. pseudomallei* that emphasizes the structure-activity relationship and provides insight into the binding mechanism of peptides on living *B. pseudomallei* and model membranes.

![Figure 7. Spatial orientations of four antimicrobial peptides in membrane bilayers calculated with the PPM 2.0 program.](http://www.plosntds.org/doi/10.1371/journal.pntd.0002267.g007)

**Figure 7.** Spatial orientations of four antimicrobial peptides in membrane bilayers calculated with the PPM 2.0 program. Membrane binding modes were calculated for the predicted α-helical conformations of CA-MA (A), RTA3 (B), and BMAP-18 (C) and for the predicted β-hairpin structure of bactenecin stabilized by the disulfide Cys²⁻Cys¹¹ in the monomeric form (D) and two dimeric forms: with anti-parallel pairing of the C- and N-terminal β-strands of the monomers (E) and with parallel pairing of the N-terminal β-strands of the monomers (F). Bactenecin dimer with pairing of the N-terminal β-strands showed the deepest insertion into the hydrophobic membrane core amongst the four peptides studied. Peptides are shown as ribbon diagrams colored according to secondary structure (red for α-helix, yellow for β-strand, green for loops); basic residues (Arg, Lys, His) are shown by sticks colored blue; non-polar residues (Phe, Trp, Met, Cys, Leu, Ile, Val) are shown by sticks colored green; the hydrophobic membrane boundary (at the level of the lipid carbonyls) is represented by gray dots. Images were produced using PyMol (http://www.pymol.org/). doi:10.1371/journal.pntd.0002267.g007

![Figure 8. β-hairpin model of bactenecin in the oxidized state.](http://www.plosntds.org/doi/10.1371/journal.pntd.0002267.g008)

**Figure 8.** β-hairpin model of bactenecin in the oxidized state. Cys²⁻Cys¹¹ disulfide bond in gauche-gauche-gauche conformation is formed in the non hydrogen-bonding pair; the 3-residue β-turn is formed by Val⁶⁻Val⁷⁻Ile⁸ residues in α₁α₂α₃L conformation [56]. doi:10.1371/journal.pntd.0002267.g008
There are only two reports on peptides against *B. pseudomallei* that we can compare our work to [12,13]. In our findings, low concentrations (5–20 μM) of bactenecin, CA-MA, RTA3 and BMAP-18 were able to inhibit the growth of *B. pseudomallei* close to 100%. This is a significant finding, given that in previous studies it required 100 μM of LL-37 or LL-31 for equivalent activity. However, LL-37 and LL-31 exhibited faster long-term killing kinetics than the four peptides when compared at 20 μM concentration [13]. Also, when compared with previous studies, our peptides exhibited a similar extent of biofilm inhibition as LL-37 and LL-31 [13]. With respect to mode of action, Kanthawong et al. [13] showed that LL-37 and LL-31 caused membrane blebbing when observed by freeze-fracture electron microscopy, whereas our study provides substantially more insight into the mechanism of action of the four peptides as discussed below.

The chronological events leading to bacterial killing begins with the attachment of the peptide to the outer membrane, which involves LPS-binding, followed by a cascade of events including membrane permeabilization, which leads to cell death. In PMB-BFY displacement assays, bactenecin clearly showed an ability to bind LPS about 3-fold better than CA-MA, RTA3 and BMAP-18 (Fig. 4A). Once docked, all of the tested peptides caused permeability of the outer membrane to different extents, with BMAP-18 being most effective (Fig. 4B). Further disruption of the inner membrane was demonstrated to be most efficient with bactenecin at extended time points (1–2 h). BMAP-18, on the other hand, quickly penetrated the inner membrane, but the rate appeared to slightly decline at longer time points. It should be noted here that the lactose-permease-deficient strain, *E. coli* MG 1655, was used as a representative model of live *B. pseudomallei* for the inner membrane assay. Therefore, it may not directly reflect the ability of the peptides to actually cross the inner membrane of *B. pseudomallei*. We still don’t have an explanation as to why bactenecin did not show effective outer membrane permeabilization but still was the most effective in the rest of the assays we tested. Therefore, in addition to observations on live *B. pseudomallei* and live *E. coli* MG 1655 cells, we further investigated the peptide-membrane interaction in order to better understand why bactenecin is the most efficient peptide in killing from a mechanistic point of view. We observed the interactions between the peptides of interest and model membranes and found that bactenecin could cause almost twice as much leakage than the others (Fig. 5A). The leakage appeared not to directly correlate with greater fluidity of the phospholipid bilayers (Fig. 5B).

Taking all the evidence together, we found that stronger permeability leads to slightly better bactericidal activity (Fig. 1) of bactenecin when compared to other peptides and also CAZ. However, the difference in bactenecin effectiveness compared to the other peptides studied was most apparent in the long term time-kill assay (Fig. 2). A greater than 3-log reduction in cell growth (CFUs) was observed only after treatment of cells with 20 μM bactenecin but not the other peptides, which demonstrated strong bactericidal activity of bactenecin over extended incubation times (Fig. 2A). Moreover, a complete inhibition of cell growth was observed at 50 μM bactenecin and CA-MA, indicating that the bacterial cell killing by the peptides is concentration-dependent.

*B. pseudomallei* have been reported to form biofilm both in vitro and in vivo [32]. Previous studies have demonstrated that growing *B. pseudomallei* in biofilm stimulating conditions led to antimicrobial resistance [53] partially due to the slower diffusion of antibiotics into the biofilm layer [54]. In the present study, *B. pseudomallei* H777, an isolate categorized in the high biofilm-producing group [28], responded to the antimicrobial peptides tested faster than to CAZ. Significant biofilm inhibition was found within the first hour of treatment, demonstrating a faster killing effect of the peptides compared to CAZ (Fig. 3). This finding could be beneficial in the design of an alternative combined therapy consisting of classical antibiotics and peptide-based antibiotics.

With respect to our findings and previous studies, bactenecin appears to be the most promising peptide candidate for a synergism study. Reasons are that i) dimeric and higher ordered oligomers of bactenecin were found to be more stable than the monomeric form in both serum and high-salt concentrations, which represent physiological environments, ii) this oligomeric state of bactenecin exhibits stronger inhibitory activity [18,19], and iii) bactenecin displays faster kinetics than CAZ in long-term killing assays (our study). Therefore, we propose a melioidosis treatment regimen of combined CAZ with bactenecin, as from a mechanistic point of view, both agents would act in different manner and over a different period of time. The actions of the two therapeutics would then span a longer active period in killing *B. pseudomallei* in the circulation system of the body. Combined therapy should also result in fewer antibiotics needed and eventually lower the likelihood of possible drug resistance developed from long term therapy. However, further investigation both in the in vitro and *in vivo* models is required in order to explore the possibilities of the combined use of peptide and classical antibiotics in the treatment of melioidosis.

---

### Table 1. Parameters of spatial orientations in the lipid bilayer of antimicrobial peptides.

| Peptide            | Depth* (Å) | Tilt angleb (°) | ΔGtransfer (kcal/mol) | ΔGfolding (kcal/mol) | ΔGbindingc (kcal/mol) |
|--------------------|------------|-----------------|-----------------------|----------------------|-----------------------|
| RTA3               | 6.8±1.1    | 82±9            | −12.0                 | 4.2                  | −7.8                  |
| CA-MA              | 8.2±3.6    | 85±2            | −12.3                 | 0.4                  | −11.9                 |
| BMAP-18            | 5.1±0.5    | 87±2            | −6.6                  | 0                    | −6.6                  |
| Bactenecin monomer | 3.8±0.7    | 72±4            | −5.7                  | 0                    | −5.7                  |
| Bactenecin dimer   | 8.7±0.9    | 30±5            | −8.0                  | 0                    | −8.0                  |
| Bactenecin dimer   | 8.9±0.4    | 59±7            | −11.9                 | 0                    | −11.9                 |

*The parameters were calculated by the PPM server.
*bDepth of the deepest non-hydrogen atom relative to position of membrane boundary located at the level of lipid carbonyl group.
*cBinding energy (ΔGbinding) was calculated as the sum of the energy of peptide transfer from water to the lipid bilayer (ΔGtransfer) estimated by PPM and the folding energy (ΔGfolding) of an α-helix estimated by Framework; the folding energy of a β-hairpin stabilized by the disulfide was assumed to be zero.

doi:10.1371/journal.pntd.0002267.t001

---

[1655] was used as a representative model of live *B. pseudomallei*.
Our computational model of the β-hairpin structure of bactenecin is in good agreement with recent experimental studies of bactenecin interacting with phospholipid monolayers at the air-water interface [43]. In particular, the modeled 3-residue β-turn structure and disulfide bridges with gauche-gauche-gauche conformation conform to Raman spectroscopy studies, while the ability of these β-hairpins to form dimers and higher order oligomers as well as the predicted positions of the peptides in the membrane (Fig. 7E, 7F) are consistent with observations made in AFM studies of bactenecin-lipid films such as the formation of a filament-like network, the presence of carpet-like peptide domains, and holes in the phospholipid monolayer.

The slightly higher bactericidal activity of bactenecin (Figs. 1, 2) and its significantly greater membrane permeabilization ability (Fig. 4C, Fig. 5A) relative to other studied cationic peptides may be related to the multiple oligomerization states formed by self-associated β-hairpins of bactenecin. Each of these structural forms has a distinct mode of membrane binding and binds with variable degrees of affinity (Fig. 7, Table 1) and, therefore, differentially perturbs the lipid bilayer. The strong permeabilization ability of bactenecin is reminiscent of that of protegrin PG-1 which forms β-hairpin dimers and causes membrane thinning and torroidal pore formation [55]. However, elucidation of a detailed molecular mechanism of membrane permeabilization by bactenecin requires additional experimental and computational studies.

In conclusion, these results demonstrate that bactenecin, CA-MA, RTA3 and BMAP-18 are able to inhibit the growth and biofilm formation of B. pseudomallei. The strong bactericidal activity of bactenecin is attributed to its greater ability to permeabilize the membrane. Computational modeling of these peptide-membrane interactions provide support for a model in which bactenecin is able to penetrate the membrane most effectively due to its cyclical structure. The peptide bactenecin has the potential to act as a highly effective alternative to or combined with CAZ in the treatment of melioidosis. Furthermore, understanding the mechanism of bactenecin may help us better design more effective peptides that could possibly be peptide therapeutics of choice for melioidosis.

Supporting Information

Figure S1  CD spectra of peptides. The secondary structure of (black square) Bactenecin, (black triangle)BMAP-18, (black circle)CA-MA, and (black diamond) RTA3 in distill water, (open square) Bactenecin, (open triangle)BMAP-18, (open circle)CA-MA, (open diamond) RTA3 in TFE. (TIF)

Table S1  Percentage of secondary structure of peptides. The data was obtained from analysis of the CD spectrum with the Spectra Manager II software (Jasco J-815). (DOC)

Acknowledgments

The entire manuscript was edited by Dr. Pamela T. Wong, University of Michigan, USA, under the editing grant support from KKU Publication Clinic.

Author Contributions

Conceived and designed the experiments: S. Taweechaisupapong, A. L. Lomize, R. Patramanon. Performed the experiments: K. Madhongsa, O. Phophetleb, S. Nasompak, S. Pasan. Analyzed the data: K. Madhongsa, O. Phophetleb, S. Nasompak, S. Pasan, R. Patramanon. Contributed reagents/materials/analysis tools: S. Thammasirak, S. Dachang, S. Taweechaisupapong, A. L. Lomize, R. Patramanon. Wrote the paper: A. L. Lomize, R. Patramanon.

References

1. Brett PJ, Woods DE (2000) Pathogenesis of and immunity to melioidosis. Acta Tropica 74: 201–210.
2. White NJ (2003) Melioidosis. The Lancet 361: 1713–1722.
3. Dance DA, Davis TM, Wattanagoon Y, Chaowagul W, Saiphan P, et al. (1989) Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. Journal of Infectious Diseases 159: 634–660.
4. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389–395.
5. Andreu D, Rivas L (1998) Animal Antimicrobial Peptides: An Overview. Biopolymers 47: 415–433.
6. Vorland LH, Ulvatne H, Rekdal Ø, Svendsen JS (1999) Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scandinavian Journal of Infectious Diseases 31: 467–473.
7. Bowdish DM, Davidson DJ, Scott MG, Hancock RE (2005) Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49: 1727–1732.
8. Wu M, Hancock REW (1999) Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. Journal of Biological Chemistry 274: 29–35.
9. Lee JY, Yang S-T, Lee SK, Jung HH, Shin SY, et al. (2008) Salt-resistant homodimeric bactenecin, a cathelicidin-derived antimicrobial peptide. FEBS Journal 275: 3911–3920.
10. Lee JY, Yang ST, Kim HJ, Lee SK, Jung HH, et al. (2009) Different modes of antibiotic action of homodimeric and monomeric bactenecin, a cathelicidin-derived antibacterial peptide. MBM Rep 42: 596–592.
11. Lopez-Oyama AB, Taboada P, Burbaza M, Lopez-Vivero E, Vasquez V, et al. (2009) Interaction of the cationic peptide bactenecin with mixed phospholipid monolayers at the air-water interface. Journal of Colloid and Interface Science 335: 279–288.
12. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, et al. (1996) Biological activity of the cationic antimicrobial peptide. Biochimica et Biophysica Acta (BBA) 1310: 24–32.
13. Haines LR, Thomas JM, Jackson AM, Eyford BA, Razavi M, et al. (2009) Killing of Trypanosomatid Parasites by a Modified Bovine Host Defense Peptide, BMAP-18. PLoS Negl Trop Dis 3: e733.
14. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, et al. (1996) Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem 271: 20373–20381.
15. Haines LR, Thomas JM, Jackson AM, Eyford BA, Razavi M, et al. (2009) Killing of Trypanosomatid Parasites by a Modified Bovine Host Defense Peptide, BMAP-18. PLoS Negl Trop Dis 3: e733.
16. Shi SX, Liao MK, Kim KL, Hahn K-S (1997) Structure-antitumor and LPS-neutralizing activity of bovine myeloid antimicrobial peptide-18 (BMAP-18) and its analogs. Peptides 32: 1123–1130.
17. Hai Nan Y, Jacob B, Kim Y, Yub Shin S (2012) Linear bactenecin analogs with high antimicrobial activities and chloramphenicol against bacterial cells. Scientific Reports 2: 499.
18. Lee JY, Yang S-T, Lee SK, Jung HH, Shin SY, et al. (2008) Salt-resistant homodimeric bactenecin, a cathelicidin-derived antimicrobial peptide. FEBS Journal 275: 3911–3920.
19. Lee JY, Yang ST, Kim HJ, Lee SK, Jung HH, et al. (2009) Different modes of antibiotic action of homodimeric and monomeric bactenecin, a cathelicidin-derived antibacterial peptide. MBM Rep 42: 596–592.
20. Lopez-Oyama AB, Taboada P, Burbaza M, Lopez-Vivero E, Vasquez V, et al. (2009) Interaction of the cationic peptide bactenecin with mixed phospholipid monolayers at the air-water interface. Journal of Colloid and Interface Science 335: 279–288.
21. Skerlavaj B, Gennaro R, Bagella L, Merluzzi L, Risso A, et al. (1996) Biological activity of the cationic antimicrobial peptide. Biochimica et Biophysica Acta (BBA) 1310: 24–32.
22. Haines LR, Thomas JM, Jackson AM, Eyford BA, Razavi M, et al. (2009) Killing of Trypanosomatid Parasites by a Modified Bovine Host Defense Peptide, BMAP-18. PLoS Negl Trop Dis 3: e733.
23. Shi SX, Liao MK, Kim KL, Hahn K-S (1997) Structure-antitumor and LPS-neutralizing activity of bovine myeloid antimicrobial peptide-18 (BMAP-18) and its analogs. Peptides 32: 1123–1130.
24. Shin SY, Kang S-W, Lee DG, Eom SH, Song WK, et al. (2000) CRAMP Analogues Having Potent Antibiotic Activity against Bacterial, Fungal, and Tumor Cells without Hemolytic Activity. Biochemical and Biophysical Research Communications 275: 904–909.
25. Park Y, Lee DG, Jang S-H, Woo E-R, Jeong HG, et al. (2003) A Leu-Lys-rich antimicrobial peptide: activity and mechanism. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1645: 172–182.

26. Park KH, Park Y, Park HS, Hahm K-S, Shin SY (2008) Bacterial selectivity and plausible mode of anti-bacterial action of designed Pro-rich short model antimicrobial peptides. Journal of Peptide Science 14: 876-882.

27. Hawrani A, Howe RA, Wahid TR, Dempsey CE (2008) Origin of low mammalian cell toxicity in a class of highly active antimicrobial amphipathic helical peptides. J Biol Chem 283: 18363-18365.

28. Taweechaisupapong S, Kaewpa C, Arunyanart C, Kanla P, Homchampa P, et al. (2005) Virulence of Burkholderia pseudomallei does not correlate with biofilm formation. Microbial Pathogenesis 39: 77-85.

29. Leitner I, Nemeth J, Feurstein T, Abrahim A, Matzneller P, et al. (2011) The contribution of surface residues to membrane binding and ligand transfer by the z-tocopherol transfer protein (z-TTP). J Mol Biol 405: 972-988.

30. Musk DJ, Banko DA, Hergenrother PJ (2005) Hergenrother PJ. Iron Salts Perturb Biofilm Formation and Disrupt Existing Biofilms of Pseudomonas aeruginosa. Chemistry & Biology 12: 789-796.

31. Benincasa M, Pacor S, Gennaro R, Scocchi M (2009) Rapid and Reliable Detection of Antimicrobial Peptide Penetration into Gram-Negative Bacteria Based on Fluorescence Quenching. Antimicrobial Agents and Chemotherapy 53: 3501-3504.

32. Eriksson M, Nielsen PE, Good I (2002) Cell Permeabilization and Uptake of Antisense Peptide-Peptide Nucleic Acid (PNA) into Escherichia coli. J Biol Chem 277: 7144-7147.

33. Lehrer RI, Barton A, Ganz T (1988) Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. Journal of Immunological Methods 108: 153-158.

34. Sibanda BL, Thornton JM (1991) Transcriptional responses of Burkholderia cenocepacia to polymyxin B resistance in Burkholderia cenocepacia. Environmental Microbiol Reports 3: 278-285.

35. Torrent M, de la Torre Beatriz G, Nogue’s Victo`ria M, Andreu D, Boix E (2009) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 48: 4830-4842.

36. Lomize MA, Pogozheva ID, Mosberg HI (2007) The role of hydrophobic interactions in positioning of peripheral proteins in membranes. BMC Struct Biol 7: 44.

37. Zhang WN, Thakur V, Lomize AL, Pogozheva I, Panagopulo C, et al. (2011) Diffusion and activity of antibiotics against Burkholderia pseudomallei. PLoS One 6: e9196.

38. Lomize AL, Pogozheva ID, Mosberg HI (2006) Positioning of proteins in membranes: a computational approach. Protein Sci 15: 1318-1333.

39. Lomize AL, Pogozheva ID, Mosberg HI (2011) Anisotropic solvent model of the lipid bilayer: 2. Energetics of insertion of small molecules, peptides, and proteins in membranes. J Chem Inf Model 51: 930-946.

40. Lomize AL, Pogozheva ID,Mosberg HI (2009) Membrane morphology of outer membrane vesicles of Pseudomonas aeruginosa. J. Colloid Interface Sci 339: 279-289.

41. Lomize AL, Pogozheva ID, Mosberg HI (2013) Muscle movement in the phospholipid bilayer. J Chem Inf Model 53: 3510-3520.

42. Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI (2007) The role of hydrophobic interactions in positioning of peripheral proteins in membranes. BMC Struct Biol 7: 44.

43. Lomize AL, Pogozheva ID, Mosberg HI (2013) Antimicrobial Peptides against Burkholderia pseudomallei. J Chem Inf Model 53: 3510-3520.

44. Lomize AL, Pogozheva ID, Singh NP, et al. (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.

45. Loutet S, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of outer membrane vesicles of Pseudomonas aeruginosa. J Colloid Interface Sci 339: 279-289.

46. Loutet S, Musser LE, Flannagan RS, Valvano MA (2011) A two-tier model of beta-hairpin proteins in protein structures: classification and diversity in homologous structures. Meth Enzymol 502: 59-82.

47. Loutet SA, Musser LE, Flannagan RS, Valvanova MA (2011) A two-tier model of beta-hairpin proteins in protein structures: classification and diversity in homologous structures. Meth Enzymol 502: 59-82.

48. Loutet SA, Musser LE, Flannagan RS, Valvanova MA (2011) A two-tier model of beta-hairpin proteins in protein structures: classification and diversity in homologous structures. Meth Enzymol 502: 59-82.

49. Loutet SA, Musser LE, Flannagan RS, Valvanova MA (2011) A two-tier model of beta-hairpin proteins in protein structures: classification and diversity in homologous structures. Meth Enzymol 502: 59-82.

50. Loutet S, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.

51. Loutet SA, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.

52. Loutet S, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.

53. Loutet S, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.

54. Loutet S, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.

55. Loutet S, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.

56. Loutet S, Di Lorenzo F, Clarke C, Molinaro A, Valvanova MA (2011) Membrane topology of the colicin E1 channel using genetically encoded fluorescence. Biochemistry 50: 4830-4842.